InvestorsHub Logo
icon url

mojojojo

11/18/07 9:33 PM

#18859 RE: honestabe13 #18857

honestabe

You make some good points.

With regards to the Avastin PR, one thing it didn’t discuss was quality of life.

Patients were randomized to receive Avastin alone or in combination with irinotecan every other week for up to 104 weeks.

Just a guess but continuous use of these drugs couldn’t be too much fun.

Check out page 2 of this years PPHM's annual report.

mojo
icon url

until2000

11/18/07 9:36 PM

#18860 RE: honestabe13 #18857

My apologies, you just sounded so gleeful at adding to our continuing pain.
icon url

sunstar

11/18/07 9:37 PM

#18861 RE: honestabe13 #18857

honestabe, DNA has been in a downtrend for two years now.

How many PR's has DNA put out during that stretch?

You say:

>>profitable entities have a clear advantage with PR'd developments like these, and pphm keeps getting lost in theshuffle because management hasn't parlayed ANYTHING into profits....<<

DNA is a profitable, fast-growing company.

No guarantees

sunstar